|

Hyperpolarized Carbon C 13 Pyruvate Clinical Trials

5 actively recruiting trials across 2 locations

Also known as: HP C13 pyruvate, Hyperpolarized 13C-Pyruvate, Hyperpolarized Pyruvate (13C)

Pipeline

Phase 1: 4Phase 2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2
  • University of California, San Francisco1
  • Susan Chang1
  • Javier Villaneuva-Meyer, MD1

Indications

  • Cancer5
  • WHO Grade II Glioma1
  • Recurrent World Health Organization (WHO) Grade II Glioma1
  • Recurrent WHO Grade III Glioma1
  • WHO Grade III Glioma1

San Francisco, California3 trials

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

University of California, San Francisco

Phase 1
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

University of California, San Francisco

Phase 2
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

University of California, San Francisco

Phase 1

Houston, Texas2 trials

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

M D Anderson Cancer Center

Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.